Clinical Trials Logo

Solid Tumor clinical trials

View clinical trials related to Solid Tumor.

Filter by:

NCT ID: NCT00283257 Completed - Lymphoma Clinical Trials

Simultaneous Care: Linking Palliation to Clinical Trials

Start date: February 2002
Phase: N/A
Study type: Interventional

This is a multi-site randomized control trial taking place at six cancer centers. UC Davis is the lead site. Additional performance sites include the City of Hope Medical Center, Fred Hutchinson Cancer Center at the Univ. of Washington, USC Norris Cancer Center, UCSD Cancer Center, and Johns Hopkins Cancer Center. Clinical trial patients and their caregivers who are randomized to the intervention arm of the study are scheduled for three educational sessions. The sessions focus on teaching problem solving skills based on the COPE problem solving model.

NCT ID: NCT00251407 Completed - Solid Tumor Clinical Trials

Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies

Start date: September 1999
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find the highest dose of the combination of taxotere, cisplatin and CPT-11, that can be given without causing severe side effects. We also want to test the safety of this drug combination and see what effects (good and bad) it has on patients with advanced cancer for which there is no known curable treatment.

NCT ID: NCT00215501 Completed - Solid Tumor Clinical Trials

Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies

Start date: November 2001
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety of irinotecan and cisplatin in combination with either capecitabine or continuous infusion 5-fluorouracil and to see what effects (good and bad) these have on patients with unresectable, advanced solid tumors.

NCT ID: NCT00052273 Completed - Solid Tumor Clinical Trials

LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors

Start date: December 2002
Phase: Phase 1
Study type: Interventional

RATIONALE: LY317615 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth and by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining LY317615 with capecitabine may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining LY317615 with capecitabine in treating patients who have advanced solid tumors.